TME Pharma N.V. (ALTME) — Cash Flow-to-Debt Ratio
TME Pharma N.V. (ALTME) has a Cash Flow-to-Debt Ratio of -0.15x as of December 2025, meaning its operating cash flow of €-557.00K could theoretically repay 0% of its total liabilities (€3.72 Million) in one year. See TME Pharma N.V. (ALTME) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
TME Pharma N.V. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for TME Pharma N.V. across 12 annual periods. Also explore how fast is TME Pharma N.V. growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for TME Pharma N.V. (2014–2025)
Year-by-year debt coverage analysis for TME Pharma N.V.. For market capitalisation and broader financial context, see TME Pharma N.V. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.92x | €-3.42 Million | €3.72 Million | ▲ +64.5% |
| 2024 | -2.59x | €-4.63 Million | €1.79 Million | ▼ -27.8% |
| 2023 | -2.02x | €-5.63 Million | €2.79 Million | ▼ -8.5% |
| 2022 | -1.86x | €-12.14 Million | €6.51 Million | ▲ +20.7% |
| 2021 | -2.35x | €-12.38 Million | €5.27 Million | ▼ -33.0% |
| 2020 | -1.77x | €-5.22 Million | €2.96 Million | ▼ -47.9% |
| 2019 | -1.20x | €-4.29 Million | €3.59 Million | ▼ -112.9% |
| 2018 | -0.56x | €-4.00 Million | €7.12 Million | ▲ +35.8% |
| 2017 | -0.87x | €-4.24 Million | €4.85 Million | ▲ +48.0% |
| 2016 | -1.68x | €-8.99 Million | €5.35 Million | ▼ -62.9% |
| 2015 | -1.03x | €-13.48 Million | €13.07 Million | ▲ +22.7% |
| 2014 | -1.33x | €-12.46 Million | €9.33 Million | — |